Provided by Tiger Fintech (Singapore) Pte. Ltd.

Unicycive Therapeutics, Inc.

0.6639
+0.069111.62%
Post-market: 0.67010.0062+0.93%19:59 EDT
Volume:1.75M
Turnover:1.13M
Market Cap:68.91M
PE:-1.36
High:0.6800
Open:0.5948
Low:0.5901
Close:0.5948
Loading ...

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

THOMSON REUTERS
·
13 Mar

Noble Financial Sticks to Its Buy Rating for Unicycive Therapeutics (UNCY)

TIPRANKS
·
21 Feb

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

GlobeNewswire
·
20 Feb

Unicycive Therapeutics Price Target Maintained With a $4.00/Share by HC Wainwright & Co.

Dow Jones
·
29 Jan

Buy Rating for Unicycive Therapeutics Driven by Promising OLC Treatment and Reduced Pill Burden

TIPRANKS
·
29 Jan

Unicycive announces publication of patient perspectives on phosphate management

TIPRANKS
·
28 Jan

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

GlobeNewswire
·
28 Jan

Positive Buy Recommendation for Unicycive Therapeutics Driven by Promising Trial Results and Revenue Forecasts

TIPRANKS
·
08 Jan

Unicycive Therapeutics announces publication of OLC dose escalation data

TIPRANKS
·
07 Jan

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

GlobeNewswire
·
07 Jan

Unicycive announces puvlication of OLC positive bioequivalence data

TIPRANKS
·
17 Dec 2024

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

GlobeNewswire
·
17 Dec 2024

Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Simply Wall St.
·
28 Nov 2024

Unicycive Therapeutics Price Target Maintained With a $3.00/Share by Benchmark

Dow Jones
·
22 Nov 2024

Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire
·
21 Nov 2024

Strategic Market Position and FDA Milestone Propel Unicycive Therapeutics to ‘Buy’ Rating

TIPRANKS
·
15 Nov 2024